2,5,5-Trimethyloxazoline | 4195-89-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑啉类
• 英文名称: 2,5,5-Trimethyloxazoline
• 英文别名: 2,5,5-trimethyl-4,5-dihydro-oxazole；2,5,5-Trimethyl-4,5-dihydro-oxazol；2,5,5-Trimethyl-Δ²-oxazolin；2,5,5-Trimethyl-2-oxazolin；2,5,5-Trimethyloxazolin；2,5,5-Trimethyl-4,5-dihydro-1,3-oxazole；2,5,5-trimethyl-4H-1,3-oxazole
• CAS: 4195-89-5
• 化学式: C₆H₁₁NO
• 分子量: 113.159
• InChiKey: XXIYMLVQHMYCHS-UHFFFAOYSA-N

物化性质

• 沸点：
  120 °C
• 密度：
  0.899 g/cm3(Temp: 22 °C)

计算性质

• 辛醇/水分配系数(LogP)：
  0.4
• 重原子数：
  8
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.83
• 拓扑面积：
  21.6
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  2,5,5-Trimethyloxazoline 在 potassium tert-butylate 作用下， 以 六甲基磷酰三胺 为溶剂， 反应 18.0h， 生成 N-(2-methylprop-1-enyl)acetamide
  参考文献：
  名称：

  Schmitt, Guenter; Ebertz, Wolfgang, Angewandte Chemie, 1982, vol. 94, # 8, p. 650 - 651

  摘要：

  DOI：
• 作为产物：
  描述：

  N-(2-methyl-2-propenyl)acetamide 在 硫酸 作用下， 生成 2,5,5-Trimethyloxazoline
  参考文献：
  名称：

  Chemistry of Ethylenimine. IV. Pyrolysis of 1-Acyl Derivatives of 2,2-Dimethylethylenimine¹

  摘要：

  DOI：

  10.1021/jo01095a022

文献信息

• [EN] THERAPEUTIC COMPOUNDS AND USES THEREOF<br/>[FR] COMPOSÉS THÉRAPEUTIQUES ET LEURS UTILISATIONS
  申请人：GENENTECH INC

  公开号：WO2016123391A1

  公开（公告）日：2016-08-04

  The present invention relates to compounds of formula (I): and to salts thereof, wherein R1-R6 have any of the values defined in the specification, and compositions and uses thereof. The compounds are useful as inhibitors of TAF1. Also included are pharmaceutical compositions comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof, and methods of using such compounds and salts in the treatment of various TAF1-mediated disorders.

  本发明涉及式(I)的化合物及其盐，其中R1-R6具有规范中定义的任何值，以及其组合物和用途。这些化合物可用作TAF1的抑制剂。还包括包含式(I)的化合物或其药学上可接受的盐的药物组合物，以及在治疗各种TAF1介导的疾病中使用这些化合物和盐的方法。
• [EN] QUINOXALINE AND PYRIDOPYRAZINE DERIVATIVES AS PI3KBETA INHIBITORS<br/>[FR] DÉRIVÉS DE QUINOXALINE ET DE PYRIDOPYRAZINE À TITRE D'INHIBITEURS DE PI3KΒ
  申请人：JANSSEN PHARMACEUTICA NV

  公开号：WO2017060406A1

  公开（公告）日：2017-04-13

  The present invention relates to substituted quinoxaline and pyridopyrazine derivatives of Formula (I) wherein the variables have the meaning defined in the claims. The compounds according to the present invention are useful as pI3Kβ inhibitors. The invention further relates to pharmaceutical compositions comprising said compounds as an active ingredient as well as the use of said compounds as a medicament.

  本发明涉及式（I）所示的取代喹喹啉和吡啶吡嘧啶衍生物，其中变量的含义如权利要求中所定义。根据本发明的化合物可用作pI3Kβ抑制剂。本发明还涉及含有上述化合物作为活性成分的药物组合物，以及将上述化合物用作药物的用途。
• Imine Compounds
  申请人：Koerber Karsten

  公开号：US20130184320A1

  公开（公告）日：2013-07-18

  The present invention relates to imine compounds which are useful for combating or controlling invertebrate pests, in particular arthropod pests and nematodes. The invention also relates to a method for controlling invertebrate pests by using these compounds and to plant propagation material and to an agricultural and a veterinary composition comprising said compounds.

  本发明涉及亚胺化合物，其可用于对抗或控制无脊椎动物害虫，特别是节肢动物害虫和线虫。本发明还涉及使用这些化合物控制无脊椎动物害虫的方法，以及包括该化合物的植物繁殖材料、农业和兽医组合物。
• DIHYDROPYRROLOPYRIMIDINE DERIVATIVES
  申请人：PFIZER INC.

  公开号：US20150291604A1

  公开（公告）日：2015-10-15

  The present invention relates to compounds of formula (X) or pharmaceutically acceptable salts thereof, wherein R 1 -R 50 , a, b, d, e, f, g, h, i, j, k, l, o, p, q, r, s, t, u, y, and z are defined herein. The novel dihydropyrrolopyrimidine derivatives are useful in the treatment of abnormal cell growth, such as cancer, in mammals. Additional embodiments relate to pharmaceutical compositions containing the compounds and to methods of using the compounds and compositions in the treatment of abnormal cell growth in mammals.

  本发明涉及式（X）化合物或其药学上可接受的盐，其中R1-R50，a，b，d，e，f，g，h，i，j，k，l，o，p，q，r，s，t，u，y和z在此定义。这种新型二氢吡咯吡咪啉衍生物在哺乳动物的异常细胞生长，如癌症治疗中有用。其他实施例涉及含有该化合物的制药组合物以及在哺乳动物中治疗异常细胞生长的方法。
• Quinoxaline and pyridopyrazine derivatives as PI3K-beta inhibitors
  申请人：JANSSEN PHARMACEUTICA NV

  公开号：US11130751B2

  公开（公告）日：2021-09-28

  The present invention relates to substituted quinoxaline and pyridopyrazine derivatives of Formula (I) wherein the variables have the meaning defined in the claims. The compounds according to the present invention are useful as pI3Kβ inhibitors. The invention further relates to pharmaceutical compositions comprising said compounds as an active ingredient as well as the use of said compounds as a medicament.

  本发明涉及式 (I) 的取代喹喔啉和吡啶并吡嗪衍生物 其中的变量具有权利要求中定义的含义。根据本发明的化合物可用作 pI3Kβ 抑制剂。本发明还涉及包含上述化合物作为活性成分的药物组合物以及上述化合物作为药物的用途。